Consistent with the proposed hypothesis that bivalent binding will increase tumour retention, optimal targeting of ALM in vivo requires expression of both ErbB2 and ErbB3 on the tumour cell surface (Figure 4A). This evidence concerns the gene ERBB2 and neoplasm.